Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?

Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?

Breast oncologists are intimately familiar with managing treatment-related adverse events of endocrine, cytotoxic and targeted therapies, but the approval of immune-checkpoint inhibitors (ICIs) for metastatic triple-negative breast cancer (TNBC) poses new challenges. Herein, we discuss the safety of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Clinical oncology 2019-07, Vol.16 (7), p.399-400
Hauptverfasser: D’Abreo, Nina, Adams, Sylvia
Format: Artikel
Sprache:eng
Schlagworte:
692/4028/67/1059/2325
692/4028/67/1347
692/700/565/2194
Breast cancer
Comment
Cytotoxicity
Drug therapy
Immune checkpoint inhibitors
Immunotherapy
Medicine
Medicine & Public Health
Metastases
Metastasis
Oncology
Safety and security measures
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Breast oncologists are intimately familiar with managing treatment-related adverse events of endocrine, cytotoxic and targeted therapies, but the approval of immune-checkpoint inhibitors (ICIs) for metastatic triple-negative breast cancer (TNBC) poses new challenges. Herein, we discuss the safety of ICIs in metastatic TNBC, with an emphasis on immune-related adverse events.
ISSN:1759-4774
1759-4782
DOI:10.1038/s41571-019-0216-2